Comparative risk of retinal microvascular disorders in patients with gout initiating febuxostat versus allopurinol: a population-based cohort study

Abstract Despite recent accumulation on cardiovascular (CV) safety data on xanthine oxidase inhibitors (XOIs) among gout patients, assessment has been largely limited to macro- than micro-vascular disorders, prompting the investigation on the latter outcome. Therefore, we aimed to compare the risk o...

Full description

Saved in:
Bibliographic Details
Main Authors: Min Jung Kim, Jung Yoon Pyo, Se Rim Choi, Anna Shin, Hokyung Choung, You-Jung Ha, Yun Jong Lee, Eun bong Lee, Eun Ha Kang
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-00551-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849763224248909824
author Min Jung Kim
Jung Yoon Pyo
Se Rim Choi
Anna Shin
Hokyung Choung
You-Jung Ha
Yun Jong Lee
Eun bong Lee
Eun Ha Kang
author_facet Min Jung Kim
Jung Yoon Pyo
Se Rim Choi
Anna Shin
Hokyung Choung
You-Jung Ha
Yun Jong Lee
Eun bong Lee
Eun Ha Kang
author_sort Min Jung Kim
collection DOAJ
description Abstract Despite recent accumulation on cardiovascular (CV) safety data on xanthine oxidase inhibitors (XOIs) among gout patients, assessment has been largely limited to macro- than micro-vascular disorders, prompting the investigation on the latter outcome. Therefore, we aimed to compare the risk of retinal microvascular disorders between allopurinol and febuxostat initiators among gout patients. Using the 2011–2019 Korean National Health Insurance service database, we conducted a cohort study on gout patients initiating allopurinol or febuxostat. The primary outcome was a composite of retinal microvascular disorders. After 1:1 propensity-score (PS) matching in non-diabetic (non-DM) and diabetic (DM) subgroups, pooled and subgroup-specific hazard ratios (HRs) and 95% confidence intervals (CIs) were reported, comparing allopurinol and febuxostat. We included 118,376 PS-matched pairs of febuxostat and allopurinol initiators (mean 57.3 years, 83.7% male; 89,642 pairs in non-DM and 28,734 pairs in DM subgroup). During a mean follow-up of 223 days, the incidence rate per 100 person-years of the primary outcomes was 0.88 among allopurinol users and 0.93 among febuxostat users. The corresponding HR (95% CI) was 0.98 (0.83–1.15). The HR (95% CI) was 0.94 (0.76–1.15) in non-DM subgroup and 1.05 (0.80–1.39) in DM subgroup. The result for DM retinopathy also showed a similar risk (HR 0.86, 95% CI 0.67–1.11). In this large population-based cohort study on patients with gout, we did not find any difference in the risk of retinal microvascular disorders between allopurinol and febuxostat initiators.
format Article
id doaj-art-11ce425b204546269ecf9584bbc5eea7
institution DOAJ
issn 2045-2322
language English
publishDate 2025-08-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-11ce425b204546269ecf9584bbc5eea72025-08-20T03:05:27ZengNature PortfolioScientific Reports2045-23222025-08-011511910.1038/s41598-025-00551-zComparative risk of retinal microvascular disorders in patients with gout initiating febuxostat versus allopurinol: a population-based cohort studyMin Jung Kim0Jung Yoon Pyo1Se Rim Choi2Anna Shin3Hokyung Choung4You-Jung Ha5Yun Jong Lee6Eun bong Lee7Eun Ha Kang8Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Hospital Boramae Medical CenterDivision of Rheumatology, Department of Internal Medicine, Seoul National University Bundang HospitalDivision of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic DiseasesDivision of Rheumatology, Department of Internal Medicine, Seoul National University Bundang HospitalDepartment of Ophthalmology, Seoul Metropolitan Government-Seoul National University Hospital Boramae Medical CenterDivision of Rheumatology, Department of Internal Medicine, Seoul National University Bundang HospitalDivision of Rheumatology, Department of Internal Medicine, Seoul National University Bundang HospitalDepartment of Internal Medicine, Seoul National University College of MedicineDivision of Rheumatology, Department of Internal Medicine, Seoul National University Bundang HospitalAbstract Despite recent accumulation on cardiovascular (CV) safety data on xanthine oxidase inhibitors (XOIs) among gout patients, assessment has been largely limited to macro- than micro-vascular disorders, prompting the investigation on the latter outcome. Therefore, we aimed to compare the risk of retinal microvascular disorders between allopurinol and febuxostat initiators among gout patients. Using the 2011–2019 Korean National Health Insurance service database, we conducted a cohort study on gout patients initiating allopurinol or febuxostat. The primary outcome was a composite of retinal microvascular disorders. After 1:1 propensity-score (PS) matching in non-diabetic (non-DM) and diabetic (DM) subgroups, pooled and subgroup-specific hazard ratios (HRs) and 95% confidence intervals (CIs) were reported, comparing allopurinol and febuxostat. We included 118,376 PS-matched pairs of febuxostat and allopurinol initiators (mean 57.3 years, 83.7% male; 89,642 pairs in non-DM and 28,734 pairs in DM subgroup). During a mean follow-up of 223 days, the incidence rate per 100 person-years of the primary outcomes was 0.88 among allopurinol users and 0.93 among febuxostat users. The corresponding HR (95% CI) was 0.98 (0.83–1.15). The HR (95% CI) was 0.94 (0.76–1.15) in non-DM subgroup and 1.05 (0.80–1.39) in DM subgroup. The result for DM retinopathy also showed a similar risk (HR 0.86, 95% CI 0.67–1.11). In this large population-based cohort study on patients with gout, we did not find any difference in the risk of retinal microvascular disorders between allopurinol and febuxostat initiators.https://doi.org/10.1038/s41598-025-00551-zFebuxostatAllopurinolRetinal microvascular disorder
spellingShingle Min Jung Kim
Jung Yoon Pyo
Se Rim Choi
Anna Shin
Hokyung Choung
You-Jung Ha
Yun Jong Lee
Eun bong Lee
Eun Ha Kang
Comparative risk of retinal microvascular disorders in patients with gout initiating febuxostat versus allopurinol: a population-based cohort study
Scientific Reports
Febuxostat
Allopurinol
Retinal microvascular disorder
title Comparative risk of retinal microvascular disorders in patients with gout initiating febuxostat versus allopurinol: a population-based cohort study
title_full Comparative risk of retinal microvascular disorders in patients with gout initiating febuxostat versus allopurinol: a population-based cohort study
title_fullStr Comparative risk of retinal microvascular disorders in patients with gout initiating febuxostat versus allopurinol: a population-based cohort study
title_full_unstemmed Comparative risk of retinal microvascular disorders in patients with gout initiating febuxostat versus allopurinol: a population-based cohort study
title_short Comparative risk of retinal microvascular disorders in patients with gout initiating febuxostat versus allopurinol: a population-based cohort study
title_sort comparative risk of retinal microvascular disorders in patients with gout initiating febuxostat versus allopurinol a population based cohort study
topic Febuxostat
Allopurinol
Retinal microvascular disorder
url https://doi.org/10.1038/s41598-025-00551-z
work_keys_str_mv AT minjungkim comparativeriskofretinalmicrovasculardisordersinpatientswithgoutinitiatingfebuxostatversusallopurinolapopulationbasedcohortstudy
AT jungyoonpyo comparativeriskofretinalmicrovasculardisordersinpatientswithgoutinitiatingfebuxostatversusallopurinolapopulationbasedcohortstudy
AT serimchoi comparativeriskofretinalmicrovasculardisordersinpatientswithgoutinitiatingfebuxostatversusallopurinolapopulationbasedcohortstudy
AT annashin comparativeriskofretinalmicrovasculardisordersinpatientswithgoutinitiatingfebuxostatversusallopurinolapopulationbasedcohortstudy
AT hokyungchoung comparativeriskofretinalmicrovasculardisordersinpatientswithgoutinitiatingfebuxostatversusallopurinolapopulationbasedcohortstudy
AT youjungha comparativeriskofretinalmicrovasculardisordersinpatientswithgoutinitiatingfebuxostatversusallopurinolapopulationbasedcohortstudy
AT yunjonglee comparativeriskofretinalmicrovasculardisordersinpatientswithgoutinitiatingfebuxostatversusallopurinolapopulationbasedcohortstudy
AT eunbonglee comparativeriskofretinalmicrovasculardisordersinpatientswithgoutinitiatingfebuxostatversusallopurinolapopulationbasedcohortstudy
AT eunhakang comparativeriskofretinalmicrovasculardisordersinpatientswithgoutinitiatingfebuxostatversusallopurinolapopulationbasedcohortstudy